LCI699, a Potent 11β-hydroxylase Inhibitor, Normalizes Urinary Cortisol in Patients With Cushing's Disease: Results From a Multicenter, Proof-of-Concept Study-Reference-Cited by-同舟云学术

LCI699, a Potent 11β-hydroxylase Inhibitor, Normalizes Urinary Cortisol in Patients With Cushing's Disease: Results From a Multicenter, Proof-of-Concept Study

Published:2014-04-01 Issue:4 Volume:99 Page:1375-1383
ISSN:0021-972X
Container-title:The Journal of Clinical Endocrinology & Metabolism
language:en
Short-container-title:

Author:

Bertagna Xavier¹,Pivonello Rosario²,Fleseriu Maria³,Zhang Yiming⁴,Robinson Paul⁵,Taylor Ann⁶,Watson Catherine E.⁶,Maldonado Mario⁷,Hamrahian Amir H.⁸,Boscaro Marco⁹,Biller Beverly M. K.¹⁰

Affiliation:

1. Department of Endocrinology (X.B.), Centre de Référence des Maladies Rares de la Surrénale, Hôpital Cochin, Faculté de Médecine Paris Descartes, Université Paris 5, Paris 75014, France

2. Dipartimento di Medicina Clinica e Chirurgia (R.P.), Università Federico II di Napoli, IT-80131, Naples, Italy

3. Department of Medicine and Neurological Surgery (M.F.), Northwest Pituitary Center, Oregon Health and Science University, Portland, Oregon 97239-3098

4. Novartis Pharmaceuticals Corporation (Y.Z.), East Hanover, New Jersey 07936

5. Novartis Pharmaceuticals UK Limited (P.R.), Horsham, West Sussex, RH12 5AB, United Kingdom

6. Novartis Institutes for BioMedical Research (A.T., C.E.W.), Cambridge, Massachusetts 02139

7. Clinical Development (M.M.), Oncology Business Unit, Novartis Pharma AG, CH-4002 Basel, Switzerland

8. Department of Endocrinology, Diabetes, and Metabolism (A.H.H.), Cleveland Clinic Foundation, Cleveland, Ohio 44106

9. Division of Endocrinology (M.B.), Polytechnic University of Marche, 60121 Ancona, Italy

10. Neuroendocrine Clinical Center (B.M.K.B.), Massachusetts General Hospital, Boston, Massachusetts 02114

Publisher

The Endocrine Society

Subject

Biochemistry (medical),Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Link

http://academic.oup.com/jcem/article-pdf/99/4/1375/9049059/jcem1375.pdf

Reference24 articles.

1. Cushing's syndrome;Pivonello;Endocrinol Metab Clin North Am,2008

2. Cushing's syndrome;Newell-Price;Lancet,2006

3. Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement;Biller;J Clin Endocrinol Metab,2008

4. Management of Cushing disease;Tritos;Nat Rev Endocrinol,2011

5. Novartis Pharma AG. Signifor Summary of Product Characteristics. 2012. Available at: http://www.signifor.com/european-product-characteristics.jsp. Accessed February 5, 2014.

Cited by 161 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging trends in small molecule inhibitors targeting aldosterone synthase: A new paradigm in cardiovascular disease treatment;European Journal of Medicinal Chemistry;2024-08

2. Efficacy and Safety of Osilodrostat in Managing Cushing’s Syndrome: A Systematic Review and Meta-Analysis;Indian Journal of Endocrinology and Metabolism;2024-05

3. Current and Emerging Pharmacological Therapies for Cushing's Disease;Current Pharmaceutical Design;2024-03

4. Fluorinated aldosterone synthase (CYP11B2)-inhibitors for differential diagnosis between bilateral and unilateral conditions of primary aldosteronism;Bioorganic & Medicinal Chemistry Letters;2023-11

5. Selectivity of osilodrostat as an inhibitor of human steroidogenic cytochromes P450;The Journal of Steroid Biochemistry and Molecular Biology;2023-07